News
Beam says its base-editing drug has met its goals in a phase 1/2 trial in genetic disease AATD, and it wants to raise $500m to take it forward ...
MoonLake secures $500m in financing for lead inflammatory disease drug sonelokimab while AIRNA, Atsena, and Neurona complete $100m+ private rounds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback